JPWO2020097625A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020097625A5 JPWO2020097625A5 JP2021524438A JP2021524438A JPWO2020097625A5 JP WO2020097625 A5 JPWO2020097625 A5 JP WO2020097625A5 JP 2021524438 A JP2021524438 A JP 2021524438A JP 2021524438 A JP2021524438 A JP 2021524438A JP WO2020097625 A5 JPWO2020097625 A5 JP WO2020097625A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- breast cancer
- pharmaceutical combination
- eribulin
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 36
- 201000011510 cancer Diseases 0.000 claims 32
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 22
- 229960003649 eribulin Drugs 0.000 claims 21
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 20
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 claims 9
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 238000002512 chemotherapy Methods 0.000 claims 8
- 230000010076 replication Effects 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 201000003076 Angiosarcoma Diseases 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000007207 Epithelioid hemangioendothelioma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 4
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 4
- 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 4
- 208000018142 Leiomyosarcoma Diseases 0.000 claims 4
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 208000027868 Paget disease Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 4
- 208000014581 breast ductal adenocarcinoma Diseases 0.000 claims 4
- 201000010881 cervical cancer Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 4
- 229960000439 eribulin mesylate Drugs 0.000 claims 4
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 claims 4
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 4
- 239000005556 hormone Substances 0.000 claims 4
- 201000004653 inflammatory breast carcinoma Diseases 0.000 claims 4
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 4
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 claims 4
- 201000010985 invasive ductal carcinoma Diseases 0.000 claims 4
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 208000027202 mammary Paget disease Diseases 0.000 claims 4
- 230000001394 metastastic effect Effects 0.000 claims 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000007282 progesterone-receptor negative breast cancer Diseases 0.000 claims 4
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 claims 4
- 230000000306 recurrent effect Effects 0.000 claims 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 4
- 208000036907 triple-positive breast carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims 4
- 239000013059 antihormonal agent Substances 0.000 claims 3
- 102100032187 Androgen receptor Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 108010080146 androgen receptors Proteins 0.000 claims 2
- 230000000593 degrading effect Effects 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 claims 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 108010069236 Goserelin Proteins 0.000 claims 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
- 108010000817 Leuprolide Proteins 0.000 claims 1
- 229940083324 Selective androgen receptor modulator Drugs 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- 229940125641 estrogen receptor degrader Drugs 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229960002913 goserelin Drugs 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 229960004296 megestrol acetate Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- 239000000849 selective androgen receptor modulator Substances 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758388P | 2018-11-09 | 2018-11-09 | |
| US62/758,388 | 2018-11-09 | ||
| PCT/US2019/061010 WO2020097625A1 (en) | 2018-11-09 | 2019-11-12 | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506829A JP2022506829A (ja) | 2022-01-17 |
| JP2022506829A5 JP2022506829A5 (https=) | 2022-11-21 |
| JPWO2020097625A5 true JPWO2020097625A5 (https=) | 2022-11-21 |
Family
ID=70612537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524438A Pending JP2022506829A (ja) | 2018-11-09 | 2019-11-12 | エリブリンと選択的ｃｄｋ４／６阻害剤との組合せを使用する癌の処置のための治療レジメン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210267986A1 (https=) |
| EP (1) | EP3877422A4 (https=) |
| JP (1) | JP2022506829A (https=) |
| CN (1) | CN113271977A (https=) |
| WO (1) | WO2020097625A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102051881B1 (ko) * | 2010-10-25 | 2019-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| MX2015007185A (es) * | 2012-12-04 | 2017-09-05 | Eisai R&D Man Co Ltd | Uso de eribulina en el tratamiento de cancer de pecho. |
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| AU2015225436A1 (en) * | 2014-03-03 | 2016-09-08 | Eisai R&D Management Co., Ltd. | Use of eribulin and mTOR inhibitors as combination therapy for the treatment of cancer |
| WO2015161285A1 (en) * | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| RU2699545C2 (ru) * | 2014-05-28 | 2019-09-06 | ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД | Применение эрибулина в лечении рака |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US20160166536A1 (en) * | 2014-12-12 | 2016-06-16 | Northwestern University | Combination therapy for the treatment of cancer |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| WO2018005533A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| EP3487492A4 (en) * | 2016-07-20 | 2020-03-11 | Eisai R&D Management Co., Ltd. | USE OF ERIBULIN AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER |
| IL303038B2 (en) * | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| EP3565558B1 (en) * | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| US20180371021A1 (en) * | 2017-05-11 | 2018-12-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US20200129473A1 (en) * | 2017-07-21 | 2020-04-30 | Eisai R&D Management Co., Ltd. | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer |
-
2019
- 2019-11-12 JP JP2021524438A patent/JP2022506829A/ja active Pending
- 2019-11-12 EP EP19881900.5A patent/EP3877422A4/en not_active Withdrawn
- 2019-11-12 WO PCT/US2019/061010 patent/WO2020097625A1/en not_active Ceased
- 2019-11-12 CN CN201980088426.8A patent/CN113271977A/zh active Pending
-
2021
- 2021-05-07 US US17/315,011 patent/US20210267986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230330106A1 (en) | Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant | |
| BR112020010435A2 (pt) | uso de inibidor da parp no tratamento de câncer de ovário ou câncer de mama resistente à quimioterapia | |
| CN109069469A (zh) | 治疗癌症的方法 | |
| CN111184863A (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2020097625A5 (https=) | ||
| AU2017245302B2 (en) | Pharmaceutical combinations | |
| EP3654967A1 (en) | Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer | |
| BR112021014820A2 (pt) | Uso da composição contendo inibidor de cdk4/6 em combinação com anastrozol na preparação de medicamento para tratar doenças tumorais | |
| TWI709402B (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 | |
| WO2005092385A2 (en) | Combination therapy of azd2171 and a taxane | |
| CN110585429B (zh) | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途 | |
| CN111757736B (zh) | 治疗鼻咽癌的喹啉衍生物 | |
| Takeshita et al. | Efficacy of preoperative chemotherapy with paclitaxel, carboplatin, and cetuximab during the surgery waiting period for resectable oral cancer | |
| CN111939165A (zh) | 非天然人参皂苷3β-O-Glc-DM治疗脑瘤的用途 | |
| RU2777519C2 (ru) | Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы | |
| HK40110657A (zh) | 用於治疗癌症的cdk4抑制剂 | |
| JPWO2023100070A5 (https=) | ||
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| Fernandes et al. | Personalization of Endocrine Therapy in Hormone Receptor-Positive Breast Cancer | |
| CN118615305A (zh) | 3β-O-Glc-DM在抑制或治疗耐药型胶质母细胞瘤中的应用 | |
| JPWO2022177844A5 (https=) | ||
| JP2024506348A (ja) | Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療 | |
| JP2023549272A (ja) | 癌を治療するためのトランス－［テトラクロリドビス（１ｈ－インダゾール）ルテニウム酸ナトリウム（ｉｉｉ）］の使用 | |
| AU2014264318B2 (en) | Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck | |
| HK40066922A (zh) | 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌 |